Management of fibromyalgia

Annals of Internal Medicine

Volumn 131, Issue 11, 1999, Pages 850-858

  Leventhal, Lawrence J ^a  

^a GRADUATE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYBUTYRIC ACID; 5 HYDROXYTRYPTOPHAN; ALPRAZOLAM; AMITRIPTYLINE; ANALGESIC AGENT; ANTIDEPRESSANT AGENT; ANTIINFLAMMATORY AGENT; BROMAZEPAM; CALCITONIN; CITALOPRAM; CYCLOBENZAPRINE; FLUOXETINE; GROWTH HORMONE; IBUPROFEN; LIDOCAINE; NAPROXEN; NORADRENALIN; ONDANSETRON; OPIATE; PREDNISONE; S ADENOSYLMETHIONINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SUBSTANCE P; TENOXICAM; TRAMADOL; TROPISETRON; TRYPTOPHAN; UNINDEXED DRUG; VENLAFAXINE;

BEHAVIOR THERAPY; CLINICAL TRIAL; COGNITIVE THERAPY; ELECTROACUPUNCTURE; EXERCISE; FEEDBACK SYSTEM; FIBROMYALGIA; GASTROINTESTINAL SYMPTOM; HUMAN; HYPNOSIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; SLEEP DISORDER;

EID: 0033534077     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-131-11-199912070-00009     Document Type: Review

References (119)

1. Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum. 1998;41:778-99.
2. Wolfe F. Fibromyalgia: the clinical syndrome. Rheum Dis Clin North Am. 1989;15:1-18.
3. Simms RW, Cahill L, Prashker M, Meenan RF. The direct costs of fibromyalgia treatment: comparison with rheumatoid arthritis and osteoarthritis. Journal of Musculoskeletal Pain. 1995;3:127-32.
4. Wolfe F, Anderson J, Harkness D, Bennett RM, Caro XJ, Goldenberg DL, et al. A prospective, longitudinal, multicenter study of service utilization and costs in fibromyalgia. Arthritis Rheum 1997;40:1560-70.
5. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee Arthritis Rheum. 1990;33:160-72.
6. Yunus M, Masi AT, Calabro JJ, Miller KA, Feigenbaum SL. Primary fibromyalgia (fibrositis): clinical study of 50 patients with matched normal controls. Semin Arthritis Rheum. 1981;11:151-71.
7. Moldofsky H. Sleep and fibrositis syndrome. Rheum Dis Clin North Am. 1989;15:91-103.
8. Moldofsky H. Sleep-wake mechanisms in fibrositis. J Rheumatol Suppl. 1989;16:47-8.
9. Gupta MA, Moldofsky H. Dysthymic disorder and rheumatic pain modulation disorder (fibrositis syndrome): a comparison of symptoms and sleep physiology. Can J Psychiatry. 1986;31:608-16.
10. Saskin P, Moldofsky H, Lue FA. Sleep and posttraumatic rheumatic pain modulation disorder (fibrositis syndrome). Psychosom Med. 1986;48:319-23.
11. Moldofsky H, Scarisbrick P, England R, Smythe H. Musculoskeletal symptoms and non-REM sleep disturbance in patients with "fibrositis syndrome" and healthy subjects. Psychosom Med. 1975;37:341-51.
12. Leventhal L, Freundlich B, Lewis J, Gillen K, Henry J, Dinges D. Controlled study of sleep parameters in patients with fibromyalgia. J Clin Rheumatol. 1995;1:110-3.
13. Bengtsson A, Hénriksson KG, Larsson J. Muscle biopsy in primary fibromyalgia. Light-microscopical and histochemical findings. Scand J Rheumatol. 1986;15:1-6.
14. Hénriksson KG, Bengtsson A, Larsson J, Lindström F, Thornell LE. Muscle biopsy findings of possible diagnostic importance in primary fibromyalgia (fibrositis, myofascial syndrome) [Letter]. Lancet 1982;2:1395.
15. Lund N, Bengtsson A, Thorborg P. Muscle tissue oxygen pressure in primary fibromyalgia. Scand J Rheumatol. 1986;15:165-73.
16. Bengtsson A, Henriksson KG, Larsson J. Reduced high-energy phosphate levels in the painful muscles of patients with primary fibromyalgia. Arthritis Rheum. 1986;29:817-21.
17. Bartels EM, Danneskiold-Samsoe B. Histological abnormalities in muscle from patients with certain types of fibrositis. Lancet. 1986;1:755-7.
18. Jacobsen S, Bartels EM, Danneskiold-Samsoe B. Single cell morphology of muscle in patients with chronic muscle pain. Scand J Rheumatol. 1991; 20:336-43.
19. Simms RW, Roy SH, Hrovat M, Anderson JJ, Skrinar G, LePoole SR, et al. Lack of association between fibromyalgia syndrome and abnormalities in muscle energy metabolism. Arthritis Rheum. 1994;37:794-800.
20. Jubrias SA, Bennett RM, Klug GA. Increased incidence of a resonance in the phosphodiester region of 31P nuclear magnetic resonance spectra in the skeletal muscle of fibromyalgia patients. Arthritis Rheum. 1994;37:801-7.
21. Park JH, Phothimat P, Oates CT, Hernanz-Schulman M, Olsen NJ. Use of P-31 magnetic resonance spectroscopy to detect metabolic abnormalities in muscles of patients with fibromyalgia. Arthritis Rheum. 1998;41:406-13.
22. Simms RW. Fibromyalgia is not a muscular disorder. Am J Med Sci. 1998; 315:346-50.
23. Crofford LJ, Pillemer SR, Kalogeras KT, Cash JM, Michelson D, Kling MA, et al. Hypothalamic-pituitary-adrenal axis perturbations in patients with fibromyalgia. Arthritis Rheum. 1994;37:1583-92.
24. van Denderen JC, Boersma JW, Zeinstra P, Hollander AP, van Neerbos BR. Physiological effects of exhaustive physical exercise in primary fibromyalgia syndrome (PFS): is PFS a disorder of neuroendocrine reactivity? Scand J Rheumatol. 1992;21:35-7.
25. Griep EN, Boersma JW, Lentjes EG, Prins PA, van der Korst JK, de Kloet ER. Function of the hypothalamic-pituitary-adrenal axis in patients with fibromyalgia and low back pain. J Rheumatol. 1998;25:1374-81.
26. Griep EN, Boersma JW, de Kloet ER. Altered reactivity of the hypothalamic-pituitary-adrenal axis in the primary fibromyalgia syndrome. J Rheumatol. 1993;20:469-74.
27. Adler GK, Kinsley BT, Hurwitz S, Mossey CJ, Goldenberg DL. Reduced hypothalamic-pituitary and sympathoadrenal responses to hyperglycemia in women with fibromyalgia syndrome. Am J Med 1999;106:534-43.
28. Clark S, Tindall E, Bennett RM. A double blind crossover trial of prednisone versus placebo in the treatment of fibrositis. J Rheumatol. 1985;12: 980-3.
29. Bennett RM, Clark SR, Campbell SM, Burckhardt CS. Low levels of somatomedin C in patients with the fibromyalgia syndrome: a possible link between sleep and muscle pain. Arthritis Rheum. 1992;35:1113-6.
30. Moldofsky H. Rheumatic pain modulation syndrome: the interrelationships between sleep, central nervous system serotonin, and pain. Adv Neurol. 1982;33:51-7.
31. Chase TN, Murphy DL. Serotonin and central nervous system function. Ann Rev Pharmacol Toxicol. 1983;13:181-97.
32. Moldofsky H, Warsh JJ. Plasma tryptophan and musculoskeletal pain in non-articular rheumatism ("fibrositis syndrome") Pain. 1978;5:65-71.
33. Russell IJ, Vipraio GA, Morgan WW, Bowden CL. Is there a metabolic basis for the fibrositis syndrome? Am J Med. 1986;81:50-6.
34. Russell IJ, Michalek JE, Vipraio GA, Fletcher EM, Wall K. Serum amino acids in fibrositis/fibromyalgia syndrome [Abstract]. Arthritis Rheum. 1989; 32(9Suppl):S70.
35. Russell IJ, Michalek JE, Vipraio GA, Fletcher EM, Javors MA, Bowden CA. Platelet 3H-imipramine uptake receptor density and serum serotonin levels in patients with fibromyalgia/fibrositis syndrome. Rheumatol. 1992; 19:104-9.
36. Yunus MB, Dailey JW, Masi AT, Aldag JC, Jobe PC. Abnormal transport ratio of serum tryptophan in primary fibromyalgia (PF) [Abstract] Arthritis Rheum. 1990;33(9 Suppl):S55.
37. Moldofsky H, Lue FA. The relationship of alpha and delta EEG frequencies to pain and mood in 'fibrositis' patients treated with chlorpromazine and L-tryptophan. Electroencephalogr Clin Neurophysiol. 1980;50:71-80.
38. Vaeroy H, Helle R, Forre Ø, Kåss E, Terenius L. Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: new features for diagnosis. Pain. 1988;32:21-6.
39. Welin M, Bragee B, Nyberg F, Kristiansson M. Elevated substance P levels are contrasted by a decrease in Met-enkephalin-Arg-Phe levels in CSF from fibromyalgia patients [Abstract]. Journal of Musculoskeletal Pain. 1995; 3(Suppl 1):4.
40. Russell IJ, Orr MD, Littman B, Vipraio GA, Alboukrek D, Michalek JE, et al. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum. 1994;37:1593-601.
41. Bradley LA, Alberts KR, Alarcón GS, Alexander MT, Mountz JM, Weigent DA, et al. Abnormal brain regional cerebral blood flow (rCBF) and cerebrospinal fluid (CSF) levels of substance P (SP) in patients and non-patients with fibromyalgia (FM) [Abstract]. Arthritis Rheum. 1996;39(9 Suppl):S212.
42. Russell IJ, Vaeroy H, Javors M, Nyberg F. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum. 1992;35:550-6.
43. Martinez-Lavin M. Hypertrophic osteoarthropathy. Curr Opin Rheumatol. 1997;9:83-8
44. Goldstein JA, Mena I, Yunus MB. Regional cerebral blood flow (rCBF) by SPECT in chronic fatigue syndrome (CSF) with and without fibromyalgia syndrome (FMS) [Abstract]. Arthritis Rheum. 1993;36(9 Suppl):S222.
45. Mountz JM, Bradley LA, Modell JG, Alexander RW, Triana-Alexander M, Aaron LA, et al. Fibromyalgia in women. Abnormalities of regional cerebral blood flow in the thalamus and the caudate nucleus are associated with low pain threshold levels. Arthritis Rheum. 1995;38:926-38.
46. Goldenberg DL. Treatment of fibromyalgia syndrome. Rheun Dis Clin North Am. 1989;15:61-71
47. Felson DT, Goldenberg DL. The natural history of fibromyalgia. Arthritis Rheum. 1986;29:1522-6.
48. Carette S, McCain GA, Bell DA, Fam AG. Evaluation of amitriptyline in primary fibrositis A double-blind, placebo-controlled study. Arthritis Rheum. 1986;29:655-9.
49. Goldenberg DL, Felson DT, Dinerman H. A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis Rheum. 1986;29:1371-7.
50. Scudds RA, McCain GA, Rollman GB, Harth M. Improvements in pain responsiveness in patients with fibrositis after successful treatment with amitriptyline. J Rheumatol. 1989;16:98-103.
51. Jaeschke R, Adachi J, Guyatt G, Keller J, Wong B. Clinical usefulness of amitriptyline in fibromyalgia: the results of 23 N-of-1 randomized controlled trials. J Rheumatol. 1991;18:447-51.
52. Simms RW. Fibromyalgia syndrome: current concepts in pathophysiology, clinical features, and management. Arthritis Care Res. 1996;9:315-28.
53. Carette S, Bell MJ, Reynolds WJ, Haraoui B, McCain GA, Bykerk VP, et al. Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia. A randomized, double-blind clinical trial. Arthritis Rheum. 1994;37:32-40.
54. Wallace DJ. The fibromyalgia syndrome. Ann Med. 1997;29:9-21.
55. Bennett RM, Gatter RA, Campbell SM, Andrews RP, Clark SR, Scarola JA. A comparison of cyclobenzaprine and placebo in the management of fibrositis. A double-blind controlled study. Arthritis Rheum. 1988;31:1535-42.
56. Dwight MM, Arnold LM, O'Brien H, Metzger R, Morris-Park E, Keck PE Jr. An open clinical trial of venlafaxine treatment of fibromyalgia. Psychosomatics. 1998;39:14-7.
57. Geller SA. Treatment of fibrositis with fluoxetine hydrochloride (Prozac) [Letter]. Am J Med. 1989;87:594-5.
58. Finestone DH, Ober SK. Fluoxetine and fibromyalgia [Letter]. JAMA. 1990; 264:2869-70.
59. Cortet B, Houvenagel E, Forzy G, Vincent G, Delcambre B. [Evaluation of the effectiveness of serotonin (fluoxetine hydrochloride) treatment. Open study in fibromyalgia]. Rev Rhum Mal Ostéoartic. 1992;59:497-500.
60. Wolfe F, Cathey MA, Hawley DJ. A double-blind placebo controlled trial of fluoxetine in fibromyalgia. Scand J Rheumatol. 1994;23:255-9.
61. Goldenberg D, Mayskiy M, Mossey C, Ruthazer R, Schmid C. A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum. 1996;39:1852-9.
62. Norregaard J, Volkmann H, Danneskiold-Samsoe B. A randomized controlled trial of citalopram in the treatment of fibromyalgia. Pain. 1995;61: 445-9.
63. Russell IJ, Fletcher EM, Michalek JE, McBroom PC, Hester GG. Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. A double-blind, placebo-controlled study. Arthritis Rheum. 1991;34: 552-60.
64. Quijada-Carrera J, Valenzuela-Castaño A, Povedano-Gómez J, Fernández-Rodriguez A, Hernánz-Mediano W, Gutierrez-Rubio A, et al. Comparison of tenoxicam and bromazepam in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Pain. 1996;65:221-5.
65. Russell IJ, Kamin M, Sager D, Bennett RM, Schnitzer T, Green JA, et al. Efficacy of Ultram (tramadol HCI) treatment of fibromyalgia syndrome: preliminary analysis of a multi-center, randomized, placebo-controlled study [Abstract]. Arthritis Rheum. 1997;40(9 Suppl):S117.
66. Biasi G, Manca S, Manganelli S, Marcolongo R. Tramadol in the fibromyalgia syndrome: a controlled clinical trial versus placebo. Int J Clin Pharmacol Res. 1998;18:13-9.
67. Rauck RL, Ruoff GE, McMillen JI. Comparison of tramadol and acetaminopher with codeine for long-term pain management in elderly patients. Curr Ther Res. 1994;55:1417-31.
68. Russell IJ. Efficacy of ULTRAM (tramadol HCI) treatment of fibromyalgia syndrome (FMS): secondary outcomes report. TPS-FM Study Group [Abstract]. Journal of Musculoskeletal Pain. 1998;6(Suppl 2):147.
69. Katz WA. Pharmacology and clinical experience with tramadol in osteoarthritis. Drugs. 1996;52 Suppl 3:39-47.
70. Yunus MB, Masi AT, Aldag JC. Short term effects of ibuprofen in primary fibromyalgia syndrome: a double blind, placebo controlled trial. J Rheumatol. 1989;16:527-32.
71. Hong CZ, Hsueh TC. Difference in pain relief after trigger point injections in myofascial pain patients with and without fibromyalgia. Arch Phys Med Rehabil. 1996;77:1161-6.
72. Figuerola ML, Loe W, Sormani M, Barontini M. Met-enkephalin increase in patients with fibromyalgia under local treatment. Funct Neurol. 1998;13: 291-5.
73. Tavoni A, Vitali C, Bombardieri S, Pasero G. Evaluation of S-adenosylmethionine in primary fibromyalgia. A double-blind crossover study. Am J Med. 1987;83:107-10.
74. Volkmann H, Norregaard J, Jacobsen S, Danneskiold-Samsoe B, Knoke G, Nehrdich D. Double-blind, placebo-controlled cross-over study of intravenous S-adenosyl-L-methionine in patients with fibromyalgia. Scand J Rheumatol. 1997;26:206-11.
75. Caruso I, Sarzi Puttini P, Cazzola M, Azzolini V. Double-blind study of 5-hydroxytryptophan versus placebo in the treatment of primary fibromyalgia syndrome. J Int Med Res. 1990;18:201-9.
76. Bessette L, Carette S, Fossel AH, Lew RA. A placebo controlled crossover trial of subcutaneous salmon calcitonin in the treatment of patients with fibromyalgia. Scand J Rheumatol. 1998;27:112-6.
77. Samborski W, Stratz T, Lacki JK, Klama K, Mennet P, Müller W. The 5-HT3 blockers in the treatment of the primary fibromyalgia syndrome: a 10-day open study with Tropisetron at a low dose. Materia Med Pol. 1996; 28:17-9.
78. Hrycaj P, Stratz T, Mennet P, Müller W. Pathogenetic aspects of responsiveness to ondansetron (5-hydroxytryptamine type 3 receptor antagonist) in patients with primary fibromyalgia syndrome - a preliminary study. J Rheumatol. 1996;23:1418-23.
79. Bennett RM, Clark SC, Walczyk J. A randomized, double-blind, placebo-controlled study of growth hormone in the treatment of fibromyalgia. Am J Med. 1998;104:227-31.
80. Russell IJ, Michalek JE, Flechas JD, Abraham GE. Treatment of fibromyalgia syndrome with Super Malic: a randomized, double blind, placebo controlled, crossover pilot study. J Rheumatol. 1995;22:953-8.
81. Scharf MB, Hauck M, Stover R, McDannold M, Berkowitz D. Effect of gamma-hydroxybutyrate on pain, fatigue, and the alpha sleep anomaly in patients with fibromyalgia. Preliminary report. J Rheumatol. 1998;25:1986-90.
82. McCain GA, Bell DA, Mai FM, Halliday PD. A controlled study of the effects of a supervised cardiovascular fitness training program on the manifestations of primary fibromyalgia. Arthritis Rheum. 1988;31:1135-41.
83. Mengshoel AM, Komnæs HB, Førre Ø. The effects of 20 weeks of physical fitness training in female patients with fibromyalgia. Clin Exp Rheumatol. 1992;10:345-9.
84. Nichols DS, Glenn TM. Effects of aerobic exercise on pain perception, affect, and level of disability in individuals with fibromyalgia. Phys Ther. 1994;74:327-32.
85. Wigers SH, Stiles TC, Vogel PA. Effects of aerobic exercise versus stress management treatment in fibromyalgia. A 4.5 year prospective study. Scand J Rheumatol. 1996;25:77-86.
86. Martin L, Nutting A, MacIntosh BR, Edworthy SM, Butterwick D, Cook J. An exercise program in the treatment of fibromyalgia. J Rheumatol. 1996;23:1050-3.
87. Norregaard J, Lykkegaard JJ, Mehlsen J, Danneskiold-Samsoe B. Exercise training in treatment of fibromyalgia. Journal of Musculoskeletal Pain. 1997;5:71-9.
88. Ferraccioli G, Ghirelli L, Scita F, Nolli M, Mozzani M, Fontana S, et al. EMG-biofeedback training in fibromyalgia syndrome. J Rheumatol. 1987;14: 820-5.
89. Sarnoch H, Adler F, Scholz B. Relevance of muscular sensitivity, muscular activity, and cognitive variables for pain reduction associated with EMG biofeedback in fibromyalgia. Percept Mot Skills. 1997;84(3 Pt 1):1043-50.
90. Haanen HC, Hoenderdos HT, van Romunde LK, Hop WC, Mallee C, Terwiel JP, et al. Controlled trial of hypnotherapy in the treatment of refractory fibromyalgia. J Rheumatol. 1991;18:72-5.
91. Waylonis GW. Long-term follow-up on patients with fibrositis treated with acupuncture. Ohio State Med J. 1977;73:299-302.
92. Deluze C, Bosia L, Zirbs A, Chantraine A, Vischer TL. Electroacupuncture in fibromyalgia: results of a controlled trial. BMJ. 1992;305:1249-52.
93. Sprott H, Franke S, Kluge H, Hein G. Pain treatment of fibromyalgia by acupuncture [Letter]. Rheumatol Int. 1998;18:35-6.
94. NIH Consensus Conference. Acupuncture. JAMA. 1998;280:1518-24.
95. Nielson WR, Walker C, McCain GA. Cognitive behavioral treatment of fibromyalgia syndrome: preliminary findings. J Rheumatol. 1992;19:98-103.
96. Vlaeyen JW, Teeken-Gruben NJ, Goossens ME, Rutten-van Molken MP, Pelt RA, van Eek H, et al. Cognitive-educational treatment of fibromyalgia: a randomized clinical trial. I. Clinical effects. J Rheumatol. 1996;23: 1237-45.
97. Keel PJ, Bodoky C, Gerhard U, Müller W. Comparison of integrated group therapy and group relaxation training for fibromyalgia. Clin J Pain. 1998;14:232-8.
98. Singh BB, Berman BM, Hadhazy VA, Creamer P. A pilot study of cognitive behavioral therapy in fibromyalgia. Altern Ther Health Med. 1998;4: 67-70.
99. Turk DC, Okifuji A, Sinclair JD, Starz TW. Interdisciplinary treatment for fibromyalgia syndrome: clinical and statistical significance. Arthritis Care Res. 1998;11:186-95.
100. Goldenberg DL, Kaplan KH, Nadeau MG, Brodeur C, Smith S, Schmid CH. A controlled study of a stress-reduction, cognitive-behavioral treatment program in fibromyalgia. Journal of Musculoskeletal Pain. 1994;2:53-66.
101. Mengshoel AM, Forseth KØ, Haugen M, Walle-Hansen R, Førre Ø. Multidisciplinary approach to fibromyalgia. A pilot study. Clin Rheumatol. 1995;14:165-70.
102. White KP, Nielson WR. Cognitive behavioral treatment of fibromyalgia syndrome: a followup assessment. J Rheumatol. 1995;22:717-21.
103. Bennett RM, Burckhardt CS, Clark SR, O'Reilly CA, Wiens AN, Campbell SM. Group treatment of fibromyalgia: a 6 month outpatient program. J Rheumatol. 1996;23:521-8.
104. Maurizio SJ, Rogers JL. Recognizing and treating fibromyalgia. Nurse Pract. 1997;22:18-33.
105. Russell IJ. Fibromyalgia syndrome: approaches to management. Bul Rheum Dis. 1996;45:1-4.
106. Ling SM. Elderly patients with osteoarthritis may also have fibromyalgia syndrome [Abstract]. J Am Geriatr Soc. 1996;44:544.
107. Portenoy RK. Opioid therapy for chronic nonmalignant pain: a review of the critical issues. J Pair Symptom Manage. 1996;11:203-17.
108. The use of opioids for the treatment of chronic pain. A consensus statement from the American Academy of Pain Medicine and the American Pain Society. Clin J Pain. 1997;13:6-8.
109. Tavoni A, Jeracitano G, Cirigliano G. Evaluation of S-adenosylmethionine in secondary fibromyalgia: a double-blind study [Letter]. Clin Exp Rheumatol. 1998;16:106-7.
110. Jacobsen S, Danneskiold-Samsoe B, Andersen RB. Oral S-adenosylmethionine in primary fibromyalgia. Double-blind clinical evaluation. Scand J Rheumatol. 1991;20:294-302.
111. Russell IJ, Vipraio GA, Abraham GE. Red cell nucleotide [RCN] abnormalities in fibromyalgia syndrome [FS] [Abstract]. Arthritis Rheum. 1993;36(9 Suppl):S223.
112. Pioro-Boisset M, Esdaile JM, Fitzcharles MA. Alternative medicine use in fibromyalgia syndrome. Arthritis Care Res. 1996;9:13-7.
113. Elert JE, Rantapää-Dahlqvist SB, Henriksson-Larsén K, Lorentzon R, Gerdlé BU. Muscle performance, electromyography and fibre type composition in fibromyalgia and work-related myalgia. Scand J Rheumatol. 1992; 21:28-34.
114. Backman E, Bengtsson A, Bengtsson M, Lennmarken C, Henriksson KG. Skeletal muscle function in primary fibromyalgia. Effect of regional sympathetic blockade with guanethidine. Acta Neurol Scand. 1988;77:187-91.
115. Buckelew SP, Conway R, Parker J, Deuser WE, Read J, Witty TE, et al. Biofeedback/relaxation training and exercise interventions for fibromyalgia: a prospective trial. Arthritis Rheum. 1998;11:196-209.
116. Patel M, Gutzwiller F, Paccaud F, Marazzi A. A meta-analysis of acupuncture for chronic pain. Int J Epidemiol. 1989;18:900-6.
117. Carlsson CP, Sjölund BH. Acupuncture and subtypes of chronic pain: assessment of long-term results. Clin J Pain. 1994;10:290-5.
118. Junnila SY. Long-term treatment of chronic pain with acupuncture. Part I. Acupunct Electrother Res. 1987;12:23-36.
119. Lewis PJ. Electroacupuncture in fibromyalgia [Letter]. BMJ. 1993;306:393.